On Thursday, Goldman Sachs initiated coverage on shares of Viridian Therapeutics (NASDAQ:VRDN) with a Buy rating and a price target of $23.00. The firm highlighted the potential of Viridian's leading assets, VRDN-001 and VRDN-003, which are monoclonal antibodies targeting the insulin-like growth factor-1 receptor (IGF-1R) for the treatment of thyroid eye disease (TED). These drugs are being developed in intravenous (IV) and subcutaneous (SC) forms, respectively.
According to Goldman Sachs, despite the established standard of care (SOC) presence of Tepezza in the market, there is a significant opportunity for VRDN-003 due to its desirable subcutaneous administration form. The firm expects that strong support from clinicians for SC over IV products will benefit Viridian's drug. The analyst pointed out that VRDN-003's advantages such as half-life extension, small injection volume, and autoinjector pairing could position it well against other subcutaneous assets that do not have these features.
For VRDN-001, Goldman Sachs believes that although its shorter treatment course might have limited competitive advantages over Tepezza, it could still play a crucial role in establishing a network of payors and prescribers in anticipation of VRDN-003's launch. The firm's valuation models project that both assets could achieve approximately $1.8 billion in worldwide non-risk-adjusted peak sales, or around $798 million risk-adjusted, by the year 2040.
Goldman Sachs' optimistic outlook for Viridian Therapeutics is based on the assessment that VRDN-003 has the potential to be best-in-class for subcutaneous administration in the treatment of thyroid eye disease. The firm's Buy rating reflects confidence in the drug's market prospects and its ability to compete effectively in the evolving TED therapeutic landscape.
In other recent news, Viridian Therapeutics has reported significant advancements in its clinical programs during its Q1 2024 earnings call. The biotechnology company completed enrollment for its Phase 3 trial of the VRDN-001 program for active thyroid eye disease (TED) and is set to share top-line results in September 2024. Moreover, it plans to file a Biologics License Application (BLA) for the same program in the second half of 2025.
Viridian also made progress with its subcutaneous VRDN-003 program, following a positive Type C meeting with the FDA, with pivotal trials set to commence mid-year. The company intends to file an Investigational New Drug (IND) application for its FcRn inhibitor VRDN-006 by year-end and present non-human primate data for VRDN-008 in the second half of 2024.
InvestingPro Insights
Goldman Sachs' recent initiation of coverage on Viridian Therapeutics with a bullish outlook underscores the potential of the company's innovative treatments for thyroid eye disease (TED). Complementing this analysis, InvestingPro data reveals a nuanced financial landscape for Viridian. The company's market capitalization stands at $787.57 million, indicative of investor interest and the scale of operations. Despite facing challenges such as rapidly depleting cash reserves and weak gross profit margins, Viridian holds more cash than debt, which could provide a buffer in its ambitious development plans.
An InvestingPro Tip worth noting is that analysts have revised their earnings estimates upwards for the upcoming period, suggesting a positive shift in expectations for Viridian's financial performance. Additionally, the company's liquid assets surpass its short-term obligations, which may provide some financial flexibility in the near term. However, it's important to recognize that analysts do not anticipate the company to be profitable this year, reflecting the high costs associated with drug development and the competitive market landscape.
For investors considering a stake in Viridian Therapeutics, it's also crucial to be aware of the company's stock performance. Over the last month, the stock has experienced a decline of 20.85%, and it's currently trading at 43.53% of its 52-week high. With these insights in hand, potential investors can better gauge the timing and potential risks associated with investing in Viridian. For more detailed analysis and additional InvestingPro Tips, visit Investing.com. Readers can also use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a total of 9 additional InvestingPro Tips to inform their investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.